Grenoble Alpes University

Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy

Retrieved on: 
Jeudi, mai 23, 2024
Risk, Obesity, ESS, ResMed, Ageing, SAN, ATS, Woman, ASV, Therapy, University of California, ASX, Plan, Health care, LVEF, Coronary artery disease, Sleep, Grenoble Alpes University, Literature review, Natural language processing, Conference, CSA, Circulatory system, Meta-analysis, BMI, AHI, Clinical trial, NIV, Obstructive sleep apnea, Qualitative Research (journal), Comorbidity, Depression, NYHA, Sleep disorder, Hospital, Research, OSA, COPD, Central sleep apnea, PAP, Patient, Education, Qualitative, RMD, Prevalence, University, Overalls, Mortality, Death, Abstract, Economy, Adaptation, Quality of life, Pharmaceutical industry

SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- A number of accomplished medical and scientific experts presented critical new research on sleep conditions and their effect on cardiovascular health at the American Thoracic Society International Conference. The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits. The studies were among 26 supported by ResMed (NYSE: RMD, ASX: RMD) in collaboration with leading scientists including Michael Arzt, MD, Universitätsklinikum Regensburg, Germany; Jean-Louis Pépin, MD, Grenoble Alpes University, France; Atul Malhotra, MD, University of California, San Diego; and Holger Woehrle, Ulm Lung Centre, Germany.

Key Points: 
  • The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits.
  • Several studies demonstrated findings showing continued effectiveness of PAP therapies for patients with sleep disorder conditions like obstructive sleep apnea.
  • This finding demonstrates a correlation between the use of PAP therapy and a reduction in use of healthcare resources.
  • Two studies evaluated the effects of Adaptive Servo-Ventilation (ASV) therapy in two populations, patients with TE-CSA and patients on long-term opioid therapy.

Artmarket.com: CIHA Lyon 2024 - France. Artprice is an active sponsor of the International Congress of Art History (CIHA) which this year will be attended by a thousand researchers from over 70 countries

Retrieved on: 
Mardi, mai 7, 2024
Grenoble Alpes University, Le Puy-en-Velay, Partnership, Library, Sheela Gowda, Human, Speech, History, Le Corbusier, CIHA, INHA, Digital technology, Congress, Museum, Scientific method, Samuel Henry Kress, World Heritage Site, Ferdinand Cheval, Committee, Congress Center, Utrecht University, EHESS, Clothing, Firminy, University of Aberdeen, Materiality, ARC, Publication, Heart, Collection, CFHA, Dixit, Foreign Affairs, Abode of Chaos, Trade, Perception, Artifact, Circle, Contemporary Art Museum, University, Michelin, Ministry, UNESCO, Painting, Getty Foundation, Tourism

For France, which is hosting the 2024 Olympic Games in Paris, the CIHA will rank among the country's major events of the year.

Key Points: 
  • For France, which is hosting the 2024 Olympic Games in Paris, the CIHA will rank among the country's major events of the year.
  • With participants from over 70 countries and more than 1000 speakers, this year's CIHA will be a superb intellectual complement to the 2024 Olympic Games in Paris.
  • And, considering Artprice's contribution to Art History by enhancing art market transparency, their support of this Congress is a great honor and makes perfect sense.
  • The CIHA Lyon 2024 Congress is open to anyone interested in art, Art History and cultural heritage.

Artmarket.com: CIHA Lyon 2024 - France. Artprice is an active sponsor of the International Congress of Art History (CIHA) which this year will be attended by a thousand researchers from over 70 countries

Retrieved on: 
Mardi, mai 7, 2024
Grenoble Alpes University, Le Puy-en-Velay, Partnership, Library, Sheela Gowda, Human, Speech, History, Le Corbusier, CIHA, INHA, Digital technology, Congress, Museum, Scientific method, Samuel Henry Kress, World Heritage Site, Ferdinand Cheval, Committee, Congress Center, Utrecht University, EHESS, Clothing, Firminy, University of Aberdeen, Materiality, ARC, Publication, Heart, Collection, CFHA, Dixit, Foreign Affairs, Abode of Chaos, Trade, Perception, Artifact, Circle, Contemporary Art Museum, University, Michelin, Ministry, UNESCO, Painting, Getty Foundation, Tourism

For France, which is hosting the 2024 Olympic Games in Paris, the CIHA will rank among the country's major events of the year.

Key Points: 
  • For France, which is hosting the 2024 Olympic Games in Paris, the CIHA will rank among the country's major events of the year.
  • With participants from over 70 countries and more than 1000 speakers, this year's CIHA will be a superb intellectual complement to the 2024 Olympic Games in Paris.
  • And, considering Artprice's contribution to Art History by enhancing art market transparency, their support of this Congress is a great honor and makes perfect sense.
  • The CIHA Lyon 2024 Congress is open to anyone interested in art, Art History and cultural heritage.

KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop

Retrieved on: 
Lundi, mai 8, 2023
Research, FDA, Dental, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Travel, Attack, University, Hereditary angioedema, Grenoble Alpes University, STP, Research fellow, Angioedema, Administration, HAE, Patient, University of Toronto, Division, Internal medicine, Route of administration, St. Michael's Hospital, KALV, Immunology, Hospital, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today that it made two oral presentations and one poster presentation at the 13th C1-inhibitor Deficiency & Angioedema Workshop (C1 Workshop) in Budapest, Hungary.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today that it made two oral presentations and one poster presentation at the 13th C1-inhibitor Deficiency & Angioedema Workshop (C1 Workshop) in Budapest, Hungary.
  • The second oral presentation was based on real-world survey data collected from people with HAE and showed that only one-third of patients always carry on-demand attack treatment with them when away from home.
  • “Strong patient preference data for oral treatments over injectables reflects these challenges.
  • We believe that sebetralstat may have the potential to improve patients’ current treatment experience.

ARBONNE ANNOUNCES NEW HR LEADERSHIP APPOINTMENT

Retrieved on: 
Vendredi, avril 21, 2023
Deakin University, Senior, University of Strasbourg, Biotechnology, Human, Certification, Beauty, Growth, Government, Arbonne International, Grenoble Alpes University, Management, UMB, Arbonne

IRVINE, Calif., April 21, 2023 /PRNewswire/ -- Arbonne International, a global leader in personal care, nutrition, beauty, and wellness products, announces that Léa Baltzinger has joined Arbonne as its Chief People Officer. The new appointment complements the company's investment in cultivating culture to meet a dynamic future in direct selling while supporting Arbonne's mission. 

Key Points: 
  • IRVINE, Calif., April 21, 2023 /PRNewswire/ -- Arbonne International , a global leader in personal care, nutrition, beauty, and wellness products, announces that Léa Baltzinger has joined Arbonne as its Chief People Officer.
  • The new appointment complements the company's investment in cultivating culture to meet a dynamic future in direct selling while supporting Arbonne's mission.
  • "Léa brings tremendous global experience in human resources leadership and organizational development to our team," said Tyler Whitehead, CEO of Arbonne.
  • Baltzinger has held senior HR leadership positions in multiple industries, including hospitality, retail, consumer electronics and biotechnology.

New, Unpublished Data Reveals Impact of COVID-19 in Patients With Neurological Disorders; Renowned Neuroscientist Ettore Beghi Presents Findings in "Special Lecture on Neuro COVID," Oct 4, 2021, World Congress of Neurology 2021

Retrieved on: 
Mardi, octobre 5, 2021
Guillain–Barré syndrome, Neurological disorder, Neurodegeneration, World Federation of Neurology, Congress, European Academy of Neurology, Even and odd functions, World government, Stroke, Hospital, National, Dysexecutive syndrome, Patient, Peripheral neuropathy, University of Bern, University of Milan, Hypertension, Twitter, WCN, COVID, Death, University, Cardiovascular disease, Government budget balance, University of Innsbruck, Risk, Society, COVID-19, Grenoble Alpes University, Peripheral nervous system, SIN, Research, Association, Data, WFN, Brain, History, Organization, Time, United Kingdom, Registry, Lists of diseases, Pharmaceutical industry

Beghi's presentation, "Special Lecture on Neuro COVID," detailed both published and newly released findings of the European Academy of Neurology COVID-19 Registry (ENERGY), of which Beghi is a member.

Key Points: 
  • Beghi's presentation, "Special Lecture on Neuro COVID," detailed both published and newly released findings of the European Academy of Neurology COVID-19 Registry (ENERGY), of which Beghi is a member.
  • "COVID-19 worsens patients' functional abilities, putting them at a greater risk of premature mortality, prolonged hospitalization and persistingneurological symptoms during follow-up," he added.
  • Data also reveals that patients with neurodegenerative diseases tend to have more severe COVID cases and worse outcomes than those who do not.
  • With support from member organizations around the globe, WFN unites the world to allow patients greater access to brain health.

New, Unpublished Data Reveals Impact of COVID-19 in Patients With Neurological Disorders; Renowned Neuroscientist Ettore Beghi Presents Findings in "Special Lecture on Neuro COVID," Oct 4, 2021, World Congress of Neurology 2021

Retrieved on: 
Mardi, octobre 5, 2021
Guillain–Barré syndrome, Neurological disorder, Neurodegeneration, World Federation of Neurology, Congress, European Academy of Neurology, Even and odd functions, World government, Stroke, Hospital, National, Dysexecutive syndrome, Patient, Peripheral neuropathy, University of Bern, University of Milan, Hypertension, Twitter, WCN, COVID, Death, University, Cardiovascular disease, Government budget balance, University of Innsbruck, Risk, Society, COVID-19, Grenoble Alpes University, Peripheral nervous system, SIN, Research, Association, Data, WFN, Brain, History, Organization, Time, United Kingdom, Registry, Lists of diseases, Pharmaceutical industry

Beghi's presentation, "Special Lecture on Neuro COVID," detailed both published and newly released findings of the European Academy of Neurology COVID-19 Registry (ENERGY), of which Beghi is a member.

Key Points: 
  • Beghi's presentation, "Special Lecture on Neuro COVID," detailed both published and newly released findings of the European Academy of Neurology COVID-19 Registry (ENERGY), of which Beghi is a member.
  • "COVID-19 worsens patients' functional abilities, putting them at a greater risk of premature mortality, prolonged hospitalization and persistingneurological symptoms during follow-up," he added.
  • Data also reveals that patients with neurodegenerative diseases tend to have more severe COVID cases and worse outcomes than those who do not.
  • With support from member organizations around the globe, WFN unites the world to allow patients greater access to brain health.